文献速递主动脉疾病

Endurant支架系统上市后研究三年结果

Three-Year Results of the Endurant Stent Graft System Post Approval Study.
PubMed 文献 · Ann Vasc Surg · 2018-03-02

ENGAGE上市后研究前瞻性纳入2011年8月至2012年6月24个中心178例接受Endurant支架行EVAR的患者,中位随访37个月,3年动脉瘤相关死亡率为1.1%,全因死亡率为13%,无动脉瘤破裂或转开放手术,6.2%接受再干预,年轻年龄与再干预相关。

要点

  • 3年动脉瘤相关死亡率为1.1%,全因死亡率为13%。
  • 随访3年内无动脉瘤破裂或转开放手术。
  • 3年再干预率为6.2%,年轻年龄与再干预相关(HR 3.3/每年轻10岁)。

核心结论

  • Endurant支架系统为肾下腹主动脉瘤提供安全、持久的治疗方式。
  • 3年内无患者发生晚期破裂或动脉瘤相关死亡,仅1/16患者接受再干预。
  • Endurant支架再干预率似乎低于其他当代支架,尽管其「使用说明」参数更宽松,但需进一步研究包括直接支架比较以指导支架选择。

研究设计与样本

  • ENGAGE上市后研究为前瞻性收集并分析临床和影像学数据的研究。
  • 2011年8月至2012年6月,24个中心共178例患者接受Endurant支架系统行EVAR。
  • 主要终点为腹主动脉瘤(AAA)相关死亡率,次要终点为全因死亡率、内漏、二次干预和器械相关并发症。
  • 采用Kaplan-Meier估计晚期结局。

主要发现

  • 178例患者中82%为男性,中位年龄71岁(IQR 66-79),中位主动脉直径55 mm(IQR 51-58 mm)。
  • 技术成功率为98.9%;3年临床和影像学随访数据分别可获于87%和74%的患者,中位随访37个月(IQR 30-38个月)。
  • 3年动脉瘤相关死亡率为1.1%,围手术期死亡2例;3年全因死亡率为13%。
  • 随访3年内无患者发生动脉瘤破裂或转开放手术;仅11例(6.2%)在3年时接受再干预。
  • 年轻年龄与再干预相关(HR 3.3/每年轻10岁,95%CI 1.3-7.6,P<0.01),而瘤颈直径、长度和成角与再干预无显著相关。

局限性

  • 原文指出需进一步研究包括直接支架比较以指导适当支架选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term data following endovascular aneurysm repair (EVAR) exist but are limited to endografts that are no longer in use. The aim of the ENGAGE Post Approval Study is to describe the long-term safety and effectiveness data following EVAR using the Endurant stent graft system. METHODS: From August 2011 to June 2012, 178 patients were enrolled and treated with the Endurant stent graft system. Clinical and radiologic data were prospectively collected and analyzed. The primary end point was abdominal aortic aneurysm (AAA)-related mortality, and secondary end points were overall mortality, endoleak, secondary interventions, and device-related complications. Kaplan-Meier estimates were used for late outcomes. RESULTS: A total of 178 patients underwent EVAR with the Endurant stent graft across 24 centers (82% men; median age 71, interquartile range [IQR] 66-79). Median aortic diameter was 55 mm (IQR 51-58 mm). There was a 98.9% technical success rate. Three-year clinical and radiographic follow-up data were available for 87% and 74% of patients, respectively. Median follow-up was 37 months (IQR 30-38 months). Three-year aneurysm-related mortality rate was 1.1%, with 2 deceased patients in the perioperative period. All-cause mortality rate at 3 years was 13%. No patients suffered from aneurysm rupture or underwent conversion to open repair through 3 years of follow-up. Only 11 patients (6.2%) had undergone reintervention at 3 years. Younger age was associated with reintervention (HR 3.3 per younger decade, 95% confidence interval 1.3-7.6, P < 0.01), but neck diameter, length, and angulation were not significantly associated with reintervention. CONCLUSIONS: The Endurant stent graft system provides a safe, durable approach to treating infrarenal AAA. No patients experienced late rupture or aneurysm-related mortality, and only 1 in 16 patients underwent reintervention by 3 years. The rate of reintervention with the Endurant graft appears to be lower than other contemporary grafts, despite more liberal "Instructions For Use" parameters, but further research including direct graft comparisons will be necessary to guide appropriate graft selection.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Deery SE, Shean KE, Pothof AB, et al. Three-Year Results of the Endurant Stent Graft System Post Approval Study. Ann Vasc Surg. 2018. PMID: 29505865. doi:10.1016/j.avsg.2017.12.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。